argenx - ADHERE study for CIDP with VYVGART® Hytrulo met primary endpoint
This morning, argenx released the highly anticipated topline data from the ADHERE study for CIDP; taking all efficacy measures together, we consider Hytrulo's efficacy to be roughly in line with Ig but with a safety and administration edge. Consequently, we foresee Hytrulo to become the dominant second-line option for CIDP patients but with significant use in first-line as well.Argenx has now successfully completed a pivotal Ph3 study for a 3rd autoantibody-driven indication, with CIDP perhaps being the most risky to date given the heterogeneity of the disease. Hence, we expect this morning's news to boost the share price.As a resultArgenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.